IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors
November 03, 2022 08:00 ET
|
IO Biotech
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech to Participate in the Jefferies London Healthcare Conference
October 31, 2022 08:00 ET
|
IO Biotech
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Announces Appointment of New Chief Financial Officer
October 13, 2022 16:05 ET
|
IO Biotech
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05, 2022 08:05 ET
|
IO Biotech
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 07:30 ET
|
IO Biotech
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Announces Second Quarter Results for 2022
August 11, 2022 17:00 ET
|
IO Biotech
Announced initiation and dosing of first patient in global Phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanomaAnnounced initiation and...
IO Biotech to Participate in the 2022 BIO International Convention
June 06, 2022 08:00 ET
|
IO Biotech
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022
May 26, 2022 17:00 ET
|
IO Biotech
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech to Participate in the Jefferies Healthcare Conference
May 23, 2022 08:00 ET
|
IO Biotech
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma
May 18, 2022 07:00 ET
|
IO Biotech
- First Patient Dosed in Proposed Registrational Trial in Melanoma- Multiple Sites to be Opened Across the United States, Australia, and Europe|- Trial Builds upon Phase 1 / 2 Results Recently...